Non clinical pharmacodynamic evaluation system of high-altitude hypoxic brain injury
10.16438/j.0513-4870.2022-1393
- VernacularTitle:高原缺氧性脑病的非临床药效学评价体系
- Author:
Meng-yao LIU
1
;
Chun-yang ZHAO
2
;
Nian-ying SHANG
1
;
Qing-li WANG
2
;
Ying PENG
1
Author Information
1. Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2. Center for Drug Evaluation, National Medical Product Administration, Beijing 100022, China
- Publication Type:Research Article
- Keywords:
high altitude hypoxic brain injury;
non-clinical efficacy;
rug discovery;
cell model;
animal model
- From:
Acta Pharmaceutica Sinica
2023;58(6):1515-1520
- CountryChina
- Language:Chinese
-
Abstract:
The air at high altitude is thin and belongs to the environment of low temperature, low oxygen and low pressure. The human brain is the most sensitive to hypoxia. Hypoxia will cause dysfunction of the central nervous system, resulting in high-altitude hypoxic brain injury, including mild high altitude headache and more destructive high altitude cerebral edema (HACE). Recently, with more and more people work and live in high altitude areas, the development of high-altitude hypoxic brain injury drugs would produce great economic value and social significance. Non clinical pharmacodynamic evaluation is the basic of drug development, which plays a key role in improving the success rate of clinical transformation and reducing the risk of clinical research. This review summarizes the cell models and animal models, and the evaluation indicators usually used to explore the candidates of high-altitude hypoxic brain injury. We aim at establishing a standardized non clinical efficacy evaluation system for high altitude hypoxic encephalopathy, and provide a standardized reference for drug development in hypoxic encephalopathy at high altitude at nonclinical stage.
